Apple COO Jeff Williams Retires From Tech Giant
Apple (AAPL) has announced that its longtime Chief Operating Officer (COO) Jeff Williams is retiring after spending 27-years at the consumer electronics giant.Current operations leader Sabih Khan will take over the COO role later in July of this year, Apple said. For his remaining time at Apple, Williams will continue to lead the company’s highly regarded design team, Apple Watch, and health initiatives. He will report to Apple CEO Tim Cook until his departure at year’s end.Williams, age 62, is the latest in a series of longtime senior executives to step down from Apple. During his career, Williams was one of the most important executives at Apple, running the company’s operations division, which is in charge of manufacturing millions of devices each year, including both the iPhone and iPad. Williams is also known for being skilled at design and led Apple’s legendary industrial design team after longtime leader Jony Ive departed the company in 2019. In a written statement, Williams said he plans to spend more time with friends and family in retirement.In his own statement, CEO Cook said of Williams, “He’s helped to create one of the most respected global supply chains in the world; launched Apple Watch and overseen its development; architected Apple’s health strategy; and led our world class team of designers with great wisdom, heart, and dedication.” AAPL stock has declined 14% this year to trade at $210.01 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


